Peripheral Nerve Injuries Pipeline Insight
DelveInsight’s,“Peripheral nerve injuries – Pipeline Insights, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Peripheral nerve injuries pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Peripheral nerve injuries Understanding
Peripheral nerve injuries: Overview
Peripheral nerve injuries (PNI) include a variety of conditions in which one or more peripheral nerves are damaged. It leads to neurological deficits distal to the level of the lesion present. Peripheral nerve injuries (PNIs) affect all age groups and damage to the peripheral nerves is known as peripheral neuropathy. The cause of PNI includes systemic diseases like diabetes, autoimmune disease or may be any localized damage, for e.g., trauma, compression, and tumors. The injuries may occur as isolated neurological conditions or, more commonly, in association with soft tissue, vascular, and/or skeletal damage. Patients with peripheral nerve injury may present with sensory deficits, loss of motor function, or a combination of both.
The Symptoms of Peripheral nerve injuries (PNI) may vary depending on the nerve fiber affected and include pain in the affected area, burning sensations and numbness. The symptoms of Peripheral nerve injuries depending on the nerve fibers affected are:
- Motor nerves. Damage to the motor nerves is typically associated with muscle weakness, painful cramps and uncontrollable muscle twitching.
- Sensory nerves. Damage in these nerve gives symptoms like numbness or tingling in hands or feet. One may feel trouble in sensing pain or changes in temperature, walking, keeping your balance with your eyes closed or fastening buttons.
- Autonomic nerves. Symptoms of damaged autonomic nerves may include excessive sweating, changes in blood pressure, the inability to tolerate heat and gastrointestinal symptoms.
Diagnosis of Peripheral nerve injuries (PNI) involves a medical history, neurological examination, and, in some cases, diagnostic tests like x-ray if fracture is suspected, CT/MRI, or electrodiagnostic examination. Conservative treatment like activity modification, splinting, and electrical stimulation are indicated in most closed injuries. In some cases nerve conduction study/neurography (analysis of a muscle's electrical activity in response to stimulation of its supplying nerve, and needle electromyography (EMG) is also performed.
Treatment for Peripheral nerve injuries (PNI) depends on the injury and other external factors including early nerve exploration and repair. Nonsurgical treatments include medications, immobilization and physical therapy. Surgical treatment may be needed if the individual has persistent neurologic symptoms. Recovery from peripheral nerve injury is often incomplete and patients may experience chronic pain.
Peripheral nerve injuries Emerging Drugs Chapters
This segment of the Peripheral nerve injuries report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Peripheral nerve injuries Emerging Drugs
- NTX-001: Neuraptive Therapeutics
Neuraptive’s Phase 2 study will evaluate the safety and efficacy of NTX-001 versus the current standard of care in upper extremity injuries. NTX-001 is being developed in the U.S. via the FDA 505 (b) (2) development pathway. In May 2020, Neuraptive Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its therapeutic product, NTX-001, for the treatment of patients with peripheral nerve injuries.
- Recombinant IL-6: Sonnet BioTherapeutics
Recombinant IL-6 also known as SON-080 is a cytokine-derived therapeutic candidate. It is under Phase 2 development for Chemotherapy Induced Peripheral Neuropathy (CIPN). The therapy is a low-dosage formulation of interleukin-6 (IL-6), a cytokine of 185 amino acids with pleiotropic functions in different tissues and organs.
Further product details are provided in the report……..
Peripheral nerve injuries: Therapeutic Assessment
This segment of the report provides insights about the different Peripheral nerve injuries drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Peripheral nerve injuries
There are approx. 10+ key companies which are developing the therapies for Peripheral nerve injuries. The companies which have their Peripheral nerve injuries drug candidates in the most advanced stage, i.e. phase III include, AxoGen.
DelveInsight’s report covers around 10+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Peripheral nerve injuries pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Peripheral nerve injuries: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Peripheral nerve injuries therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Peripheral nerve injuries drugs.
- The companies and academics are working to assess challenges and seek opportunities that could influence Peripheral nerve injuries R&D. The therapies under development are focused on novel approaches to treat/improve Peripheral nerve injuries.
- In August 2019, Sonnet BioTherapeutics announced that it has entered into an agreement with Relief Therapeutics Holding to develop atexakin alfa through the acquisition of its subsidiary, Relief Therapeutics SA, via a share exchange transaction.
Peripheral nerve injuries Report Insights
- Peripheral nerve injuries Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Peripheral nerve injuries Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Peripheral nerve injuries drugs?
- How many Peripheral nerve injuries drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Peripheral nerve injuries?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Peripheral nerve injuries therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Peripheral nerve injuries and their status?
- What are the key designations that have been granted to the emerging drugs?
- Neuraptive Therapeutics
- Fulcrum Therapeutics
- KannaLife Sciences
- Sonnet BioTherapeutics
- Ono Pharmaceutical
- SB 308
- Recombinant IL-6
- Avance Nerve Graft